• SciSparc subsidiary NeuroThera flagged three published U.S. patent applications with Clearmind covering PEA combinations with LSD, ketamine, ibogaine.
• Filings target potential treatments for depression, PTSD, pain, substance use disorders, expanding NeuroThera’s U.S. intellectual property portfolio.
• Collaboration previously generated a U.S. patent application covering MDMA combined with N-acylethanolamines for PTSD, anxiety, eating disorders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230835PRIMZONEFULLFEED9832487) on September 23, 2026, and is solely responsible for the information contained therein.